Cytokinetics' study determines dosage of cardiac myosin activator

By Lisa Kerner

Charlotte, N.C., Sept. 13 - Cytokinetics, Inc. said a phase 1 clinical trial evaluating CK-1827452, a novel cardiac myosin activator administered intravenously, determined the maximum tolerated dose to be 0.5 mg per kilogram per hour for a six-hour infusion in healthy volunteers.

At the 0.5 mg/kg/hr dose, the six-hour infusion of CK-1827452 resulted in a mean increase in left ventricular ejection fraction of 6.8 absolute percentage points compared to a placebo. The data closely tracks with that from preclinical testing of CK-1827452, according to a company news release.

The results were presented at the 10th Annual Meeting of the Heart Failure Society of America in Seattle.

The South San Francisco, Calif.-based biopharmaceutical company said it plans to hold a series of phase 2 clinical trials to further evaluate the effects of CK-1827452 in various subpopulations of heart failure patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.